PMID- 23847196
OWN - NLM
STAT- MEDLINE
DCOM- 20131113
LR  - 20240223
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 122
IP  - 11
DP  - 2013 Sep 12
TI  - Impact of donor source on hematopoietic cell transplantation outcomes for 
      patients with myelodysplastic syndromes (MDS).
PG  - 1974-82
LID - 10.1182/blood-2013-04-496778 [doi]
AB  - Allogeneic hematopoietic cell transplantation (HCT) from human leukocyte antigen 
      (HLA) matched related donor (MRD) and matched unrelated donors (MUD) produces 
      similar survival for patients with acute myelogenous leukemia. Whether these 
      results can be extended to patients with myelodysplastic syndromes (MDS) is 
      unknown. Therefore, analysis of post-HCT outcomes for MDS was performed. Outcomes 
      of 701 adult MDS patients who underwent HCT between 2002 and 2006 were analyzed 
      (MRD [n = 176], 8 of 8 HLA-A, -B, -C, -DRB1 allele matched MUD [n = 413], 7 of 8 
      MUD [ n = 112]). Median age was 53 years (range, 22-78 years). In multivariate 
      analyses, MRD HCT recipients had similar disease free survival (DFS) and survival 
      rates compared with 8 of 8 MUD HCT recipients (relative risk [RR] 1.13 [95% 
      confidence interval (CI) 0.91-1.42] and 1.24 [95% CI 0.98-1.56], respectively), 
      and both MRD and 8 of 8 MUD had superior DFS (RR 1.47 [95% CI 1.10-1.96] and 1.29 
      [95% CI 1.00-1.66], respectively) and survival (RR 1.62 [95% CI 1.21-2.17] and 
      1.30 [95% CI 1.01-1.68], respectively) compared with 7 of 8 MUD HCT recipients. 
      In patients with MDS, MRD remains the best stem cell source followed by 8 of 8 
      MUD. Transplantation from 7 of 8 MUD is associated with significantly poorer 
      outcomes.
FAU - Saber, Wael
AU  - Saber W
AD  - Center for International Blood and Marrow Transplant Research, Medical College of 
      Wisconsin, Milwaukee, WI;
FAU - Cutler, Corey S
AU  - Cutler CS
FAU - Nakamura, Ryotaro
AU  - Nakamura R
FAU - Zhang, Mei-Jie
AU  - Zhang MJ
FAU - Atallah, Ehab
AU  - Atallah E
FAU - Rizzo, J Douglas
AU  - Rizzo JD
FAU - Maziarz, Richard T
AU  - Maziarz RT
FAU - Cortes, Jorge
AU  - Cortes J
FAU - Kalaycio, Matt E
AU  - Kalaycio ME
FAU - Horowitz, Mary M
AU  - Horowitz MM
LA  - eng
GR  - 5U01HL069294/HL/NHLBI NIH HHS/United States
GR  - U24 CA076518/CA/NCI NIH HHS/United States
GR  - U24-CA76518/CA/NCI NIH HHS/United States
GR  - U01 HL069294/HL/NHLBI NIH HHS/United States
GR  - T32 HL007899/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20130711
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
CIN - Blood. 2013 Sep 12;122(11):1848-50. PMID: 24030257
MH  - Adult
MH  - Aged
MH  - *Blood Donors
MH  - Female
MH  - HLA-A Antigens/immunology
MH  - HLA-B Antigens/immunology
MH  - HLA-C Antigens/immunology
MH  - HLA-DRB1 Chains/immunology
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - Male
MH  - Multivariate Analysis
MH  - Myelodysplastic Syndromes/immunology/mortality/*surgery
MH  - Prognosis
MH  - Survival Analysis
MH  - Survival Rate
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - *Unrelated Donors
MH  - Young Adult
PMC - PMC3772501
EDAT- 2013/07/13 06:00
MHDA- 2013/11/14 06:00
PMCR- 2014/09/12
CRDT- 2013/07/13 06:00
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2013/11/14 06:00 [medline]
PHST- 2014/09/12 00:00 [pmc-release]
AID - S0006-4971(20)52954-6 [pii]
AID - 2013/496778 [pii]
AID - 10.1182/blood-2013-04-496778 [doi]
PST - ppublish
SO  - Blood. 2013 Sep 12;122(11):1974-82. doi: 10.1182/blood-2013-04-496778. Epub 2013 
      Jul 11.